Key Points
- CFO David Mutryn purchased 1,000 shares at $75.62 (worth $75,620), increasing his stake to 40,037 shares — a 2.56% rise in ownership, disclosed in an SEC filing.
- Maximus raised its quarterly dividend to $0.33 from $0.30 (ex-dividend Feb 13, payable Mar 2), implying an annualized $1.32 and a yield of about 1.8%.
- The company reported Q EPS of $1.85, beating estimates by $0.01 while revenue fell 4.1% year-over-year to $1.35B, and issued FY 2026 guidance of $8.05–$8.35 EPS.
Maximus, Inc. (NYSE:MMS - Get Free Report) CFO David Mutryn purchased 1,000 shares of the firm's stock in a transaction that occurred on Monday, February 9th. The stock was bought at an average cost of $75.62 per share, with a total value of $75,620.00. Following the completion of the purchase, the chief financial officer owned 40,037 shares of the company's stock, valued at $3,027,597.94. This represents a 2.56% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website.
Maximus Trading Up 0.0%
NYSE MMS opened at $75.09 on Tuesday. The company has a quick ratio of 2.34, a current ratio of 2.34 and a debt-to-equity ratio of 0.88. The firm has a market capitalization of $4.10 billion, a PE ratio of 11.43 and a beta of 0.56. The stock's 50 day moving average is $89.83 and its 200 day moving average is $86.59. Maximus, Inc. has a twelve month low of $63.77 and a twelve month high of $100.00.
Maximus (NYSE:MMS - Get Free Report) last released its earnings results on Thursday, February 5th. The health services provider reported $1.85 earnings per share for the quarter, topping analysts' consensus estimates of $1.84 by $0.01. Maximus had a net margin of 6.92% and a return on equity of 25.30%. The firm had revenue of $1.35 billion for the quarter, compared to the consensus estimate of $1.37 billion. During the same period in the prior year, the firm earned $1.61 EPS. The company's revenue was down 4.1% compared to the same quarter last year. Maximus has set its FY 2026 guidance at 8.050-8.350 EPS. Research analysts forecast that Maximus, Inc. will post 6.15 earnings per share for the current fiscal year.
Maximus Increases Dividend
The business also recently disclosed a quarterly dividend, which will be paid on Monday, March 2nd. Shareholders of record on Friday, February 13th will be paid a dividend of $0.33 per share. The ex-dividend date is Friday, February 13th. This is a positive change from Maximus's previous quarterly dividend of $0.30. This represents a $1.32 dividend on an annualized basis and a yield of 1.8%. Maximus's dividend payout ratio (DPR) is presently 18.26%.
Hedge Funds Weigh In On Maximus
Several institutional investors have recently added to or reduced their stakes in MMS. Norges Bank bought a new stake in Maximus in the 2nd quarter worth approximately $47,886,000. Boston Partners grew its holdings in shares of Maximus by 113.6% in the second quarter. Boston Partners now owns 657,247 shares of the health services provider's stock valued at $46,435,000 after purchasing an additional 349,529 shares in the last quarter. UBS Group AG increased its position in Maximus by 76.8% in the fourth quarter. UBS Group AG now owns 610,354 shares of the health services provider's stock worth $52,686,000 after purchasing an additional 265,095 shares during the last quarter. River Road Asset Management LLC purchased a new stake in Maximus during the second quarter valued at $18,073,000. Finally, Stephens Investment Management Group LLC lifted its position in Maximus by 49.0% during the third quarter. Stephens Investment Management Group LLC now owns 720,943 shares of the health services provider's stock valued at $65,873,000 after purchasing an additional 237,097 shares during the last quarter. Hedge funds and other institutional investors own 97.21% of the company's stock.
Analyst Ratings Changes
Several equities research analysts recently weighed in on MMS shares. Weiss Ratings reissued a "buy (b-)" rating on shares of Maximus in a research report on Monday, December 29th. Wall Street Zen cut Maximus from a "buy" rating to a "hold" rating in a research report on Saturday. Finally, Zacks Research upgraded shares of Maximus from a "hold" rating to a "strong-buy" rating in a research note on Tuesday, December 30th. One research analyst has rated the stock with a Strong Buy rating and one has assigned a Buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of "Strong Buy".
Get Our Latest Research Report on MMS
Maximus Company Profile
(
Get Free Report)
Maximus, Inc (NYSE: MMS) is a global provider of government services focused on delivering health and human services programs. The company partners with federal, state, and local agencies to administer and manage programs that support individuals and families across various stages of life. Key service areas include eligibility determination and enrollment services for Medicaid, Medicare, Children's Health Insurance Program (CHIP) and other public assistance programs, as well as call center operations, case management and program integrity solutions.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
